Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
11 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Johnson & Johnson (NYSE: JNJ ) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. Access the full call at Summary Johnson & Johnson reported st
() -- Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%. The iShares Biotechnology ETF (IBB) added 0.3%. In corporate news, Novo Nordisk (NVO) shares rose 2.5% after it said Wednesday the European Commissi
() -- Healthcare stocks were declining premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) down 0.6% and the iShares Biotechnology ETF (IBB) 0.1% lower. Elevance Health (ELV) shares were down more than 8% after the company reported lower Q2 adjusted earnings. Johnson & Johnson (JNJ) stoc
() -- Johnson & Johnson (JNJ) reported fiscal Q2 adjusted earnings Wednesday of $2.90 per diluted share, up from $2.77 a year earlier. Analysts polled by FactSet expected $2.85. Reported sales for the fiscal quarter ended June 28 were $25.31 billion, up from $23.74 billion a year earlier. Analysts surveyed by FactSet e
$JNJ Johnson & Johnson Q2 Earnings
() -- Copyright © 2026. All rights reserved. does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Health care giant Johnson & Johnson (NYSE: JNJ ) reports second-quarter financial results on Wednesday before the market opens. Here are the earnings estimates, what experts are saying and key items to watch. Johnson & Johnson Q2 Earnings Estimates Analysts expect Johnson & Johnson to report second-quarter revenue of $
Johnson & Johnson (NYSE: JNJ ) will release its second-quarter earnings report before the opening bell on Wednesday, July 15. Analysts expect the company to report quarterly earnings of $2.85 per share, up from $2.77 per share in the year-ago period. The consensus estimate for Johnson & Johnson’s quarterly revenue is $
() -- Biopharma pricing power will be the key swing factor for Q2 earnings as companies with cleaner growth outlooks continue to outperform peers facing loss-of-exclusivity headwinds, Bank of America said in a note Friday. Merck & Co (MRK), AbbVie (ABBV), Jazz Pharmaceuticals (JAZZ) and Ionis Pharmaceuticals (IONS) rem
Citi raised the firm's price target on Johnson & Johnson to $298 from $285 and keeps a Buy rating on the shares. For Q2 earnings season, given "the skittish trading environment," the firm prefers higher-quality medtech stocks that may be positioned for a catch-up trade, the analyst tells investors in a preview.
Johnson & Johnson (NYSE: JNJ ) will release its second quarter earnings report before the opening bell on Wednesday, July 15. Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings of $2.85 per share, up from $2.77 per share in the year-ago period. The consensus estimate for Johnson &